According to the trial, remdesivir didn’t quicken the recovery of patients suffering from COVID-19, nor did it prevent them from dying. In the study, 158 hospitalized patients with severe cases of coronavirus received the drug, while 79 patients in the control group did not. Out of those who took the drug, 13.9% died, compared to 12.8% of the control patients.
Prepare Now Before its too Late
Discover where products are available & compare prices
